SCHEMBL13879459

SCHEMBL13879459

O=C1NC(CCc2ccccc2)C(=O)N1c1ccccc1Cl

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.61
LMNA P02545 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
POLB P06746 3/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
TAS2R8 Q9NYW2 1/20 0.43
ATAD2 Q6PL18 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
GAA P10253 1/20 0.42
CYP2C19 P33261 1/20 0.42
MGLL Q99685 1/20 0.41
HTT P42858 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11569757 0.81 GAA (0.57) ALDH1A1LMNASMN1; SMN2L3MBTL1POLB
SCHEMBL13879413 0.81 MGLL (0.41) ALDH1A1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL13879452 0.81 ALDH1A1 (0.54) ALDH1A1LMNASMN1; SMN2L3MBTL1POLB
SCHEMBL13879563 0.81 ALDH1A1 (0.54) ALDH1A1LMNASMN1; SMN2L3MBTL1POLB
SCHEMBL11612062 0.80 KMT2A (0.50) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL13879411 0.78 ALDH1A1 (0.52) ALDH1A1LMNASMN1; SMN2L3MBTL1POLB
SCHEMBL13879564 0.76 NPSR1 (0.47) ALDH1A1POLBCYP1A2CYP3A4GAA
SCHEMBL13879403 0.76 GAA (0.56) ALDH1A1POLBTAS2R8CYP1A2CYP3A4
SCHEMBL13879503 0.75 ALDH1A1 (0.77) ALDH1A1LMNASMN1; SMN2L3MBTL1POLB
SCHEMBL13879369 0.74 ALDH1A1 (0.47) ALDH1A1LMNASMN1; SMN2L3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION EIF2AK2, HAVCR2, RTF2 ALDH1A1 1500/4885LMNA 2024/4885SMN1; SMN2 2091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.